BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360◦ Conference

Florham Park, N.J., February 9, 2025 - BeyondSpring Inc.(NASDAQ: BYSI),a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the Company will participate in the Immuno-Oncology 360^◦ (IO360^◦) Conference 2026, held February 10-12, 2026 in Boston, MA.

Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, will present on Plinabulin as a differentiated immuno-oncology asset designed to enhance PD-1/PD-LD blockade and highlight Plinabulin's unique mechanism of action and clinical development strategy.

Presentation Details:

Title: Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin

Track Number: 1. Translational Science & Biomarkers - Expanding Therapeutic Horizons

Date: Wednesday, February 11, 2026

Time: 4:55PM to 5:10PM ET

Location: Sheraton Boston Hotel, Track 1, Grand Ballroom

Following the presentation, the slides will also be available on the "Posters and Presentations" page of the Company's website.

About BeyondSpring

BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies addressing high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and other indications. Plinabulin's novel mechanism as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to resensitizing tumors resistant to checkpoint inhibitors. Learn more at https://beyondspringpharma.com.

Investor Contact: [email protected]

Media Contact: [email protected]